Monica Morrow

If it's picked up early enough, it's, it's gonna be curable.

It won't come back, right? And then I have to quote a very famous, uh, breast surgeon, Monica Morrow, for this one, 'cause when people say it's painful, she always says, "You buy new shoes and wear them-"

[laughs]

"... and that's painful," right?

And, you know, uh, you can cut something, and it looks like-- when the tumor looks like it's cut at the edge or the margin, the r- the risk that you left tumor behind is fairly high, maybe forty to fifty percent.

And so about a decade ago, there were two consensus panels that were created through the leadership of, uh, Dr. Monica Morrow, a leading breast surgeon in our country, in the world, first on invasive cancer, where it put together recommendations that are considered, uh, consensus guidelines from a panel of about twenty experts, and it was based on review of the literature, a systematic review.

Um, and in essence, it replicated what the NSAB B-3 trials had always used, which said as long as a tumor is not transected at the edge for invasive cancer, it's considered a tumor-free margin.

And then she, uh, created a panel for DCIS, of which I was a part, and that was only based on a systematic review of institutional reports.

especially if you're going to be getting an oncotype.

So there's some good data come from Monica Morrow, which says that in postmenopausal women, if you've got an oncotype, the nodal status is not very relevant when it comes to treatment decision-making in these patients there.

And so your low oncotype really trumps whether they're N1 or N0 in the post-menopausal population.

So yes, we have to be cognizant that there may well be a few patients that are missing eligibility for the drug.